Revvity, Inc. (RVTY)
(Delayed Data from NYSE)
$105.55 USD
+0.75 (0.72%)
Updated May 13, 2024 04:00 PM ET
After-Market: $105.48 -0.07 (-0.07%) 5:02 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Company Summary
Headquartered in Waltham, MA, Revvity, Inc. provides scientific instruments, consumables, and services to pharmaceutical, biomedical, environmental testing, chemical, and general industrial markets worldwide. The company was previously known as PerkinElmer till March 2023. In March, the completed the sale of its Applied, Food and Enterprise Services (AES) businessesan investment firm, New Mountain Capital, for up to $2.45 billion. Following the divesture, the company changed its name to Revvity with effect from Apr 26 and the ticker was changed from PKI to RVTY on May 16.
For the Diagnostics market, the company develops and offers products ...
Company Summary
Headquartered in Waltham, MA, Revvity, Inc. provides scientific instruments, consumables, and services to pharmaceutical, biomedical, environmental testing, chemical, and general industrial markets worldwide. The company was previously known as PerkinElmer till March 2023. In March, the completed the sale of its Applied, Food and Enterprise Services (AES) businessesan investment firm, New Mountain Capital, for up to $2.45 billion. Following the divesture, the company changed its name to Revvity with effect from Apr 26 and the ticker was changed from PKI to RVTY on May 16.
For the Diagnostics market, the company develops and offers products diagnostics, tools and applications focused on clinically-oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets.
The AES business was earlier part of Discovery & Analytical Solutions segment. However, following the divesture, the former Discovery & Analytical Solutions segment is now referred as the Life Sciences segment.
This Life Sciences segment provides products and services targeted towards the life sciences market.The company provides a broad suite of products, solutions and services that facilitate optimized workflows, increase productivity, and accelerate every stage of the drug discovery and development pipeline. Its offerings support cell, gene, and protein research and development done by global pharmaceutical, biotech and contract research organizations, as well as academic institutions.
2023 at a Glance
In 2023, the company posted revenues worth $2.75 billion, down 16.99% on a year-over-year basis. In 2023, Life Sciences revenues totaled $1.29 billion (47% of net revenues) and Diagnostics’ revenues came in at $1.46 billion (53%).
General Information
Revvity Inc
940 WINTER STREET
WALTHAM, MA 02451
Phone: 781-663-6900
Fax: 781-663-5985
Email: ir@revvity.com
Industry | Medical Services |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 8/6/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 1.15 |
Current Year EPS Consensus Estimate | 4.66 |
Estimated Long-Term EPS Growth Rate | 8.30 |
Exp Earnings Date | 8/6/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 104.80 |
52 Week High | 131.93 |
52 Week Low | 79.50 |
Beta | 1.09 |
20 Day Moving Average | 744,466.62 |
Target Price Consensus | 119.21 |
4 Week | 1.27 |
12 Week | 2.28 |
YTD | -4.13 |
4 Week | -0.66 |
12 Week | -1.97 |
YTD | -12.44 |
Shares Outstanding (millions) | 123.39 |
Market Capitalization (millions) | 12,931.59 |
Short Ratio | NA |
Last Split Date | 6/4/2001 |
Dividend Yield | 0.27% |
Annual Dividend | $0.28 |
Payout Ratio | 0.06 |
Change in Payout Ratio | 0.01 |
Last Dividend Payout / Amount | 4/18/2024 / $0.07 |
Fundamental Ratios
P/E (F1) | 22.51 |
Trailing 12 Months | 22.68 |
PEG Ratio | 2.73 |
vs. Previous Year | -2.97% |
vs. Previous Quarter | -21.60% |
vs. Previous Year | -3.70% |
vs. Previous Quarter | -6.61% |
Price/Book | 1.65 |
Price/Cash Flow | 12.69 |
Price / Sales | 4.74 |
3/31/24 | 7.37 |
12/31/23 | 7.41 |
9/30/23 | 8.30 |
3/31/24 | 4.22 |
12/31/23 | 4.18 |
9/30/23 | 4.56 |
3/31/24 | 2.23 |
12/31/23 | 2.07 |
9/30/23 | 2.01 |
3/31/24 | 1.92 |
12/31/23 | 1.77 |
9/30/23 | 1.71 |
3/31/24 | 21.14 |
12/31/23 | 21.21 |
9/30/23 | 23.00 |
3/31/24 | 5.49 |
12/31/23 | 25.20 |
9/30/23 | 26.90 |
3/31/24 | 6.90 |
12/31/23 | 6.65 |
9/30/23 | 10.37 |
3/31/24 | 63.52 |
12/31/23 | 63.79 |
9/30/23 | 61.98 |
3/31/24 | 2.83 |
12/31/23 | 2.80 |
9/30/23 | 2.82 |
3/31/24 | 0.40 |
12/31/23 | 0.40 |
9/30/23 | 0.41 |
3/31/24 | 28.74 |
12/31/23 | 28.76 |
9/30/23 | 29.06 |